Valuation: Brooks Laboratories Limited

Market Cap 1.7B 17.95M 16.03M 14.81M 13.42M 25.11M 25.53M 178M 70.57M 893M 67.38M 65.95M 2.82B P/E 2025
-28.6x
P/E 2026 4.45x
Enterprise Value 1.72B 18.15M 16.21M 14.97M 13.57M 25.38M 25.8M 180M 71.33M 903M 68.11M 66.66M 2.85B EV / Sales 2025
3.93x
EV / Sales 2026 1.3x
Free-Float
45.16%
Yield 2025 *
-
Yield 2026 -
09-16 Brooks Laboratories Limited Announces Resignation of Krutika Rane as Company Secretary and Compliance Officer (Key Managerial Personnel), Effective October 9, 2026 CI
08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-19 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day-5.29%
1 week-14.37%
Current month+3.69%
1 month-5.15%
3 months-12.31%
6 months-10.10%
Current year-27.80%
1 week 56.7
Extreme 56.7
69.4
1 month 52.97
Extreme 52.97
75.6
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
119.41
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer 58 23/01/2002
Chief Executive Officer - 01/06/2026
President 58 23/08/2023
Director TitleAgeSince
Director/Board Member 53 23/11/2022
Director/Board Member 62 10/09/2010
Director/Board Member - 23/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
-5.29%-14.37%-52.42%-47.99% 17.95M
-2.54%+1.31%+55.10%+120.84% 1,135B
-1.42%+3.23%+37.07%+74.26% 636B
+0.16%+0.08%+25.14%+97.36% 505B
-0.31%+3.09%+43.92%+64.55% 378B
-1.34%-0.47%+66.63%+40.56% 358B
-0.68%+2.65%+22.46%+51.48% 295B
-1.20%+3.04%+2.62%+26.97% 266B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 193B
Average -1.13%+0.51%+27.97%+59.01% 400.44B
Weighted average by Cap. -0.26%+2.66%+40.99%+82.13%

Financials

2025 2026
Net sales 826M 8.7M 7.77M 7.17M 6.5M 12.16M 12.36M 86.33M 34.18M 433M 32.64M 31.94M 1.36B 857M 9.03M 8.07M 7.45M 6.75M 12.63M 12.84M 89.66M 35.5M 449M 33.9M 33.17M 1.42B
Net income -99.67M -1.05M -938K -866K -785K -1.47M -1.49M -10.42M -4.13M -52.22M -3.94M -3.86M -165M 246M 2.59M 2.31M 2.14M 1.94M 3.62M 3.68M 25.71M 10.18M 129M 9.72M 9.51M 406M
Net Debt 75.39M 794K 709K 655K 594K 1.11M 1.13M 7.88M 3.12M 39.5M 2.98M 2.92M 125M 18.44M 194K 173K 160K 145K 272K 276K 1.93M 763K 9.66M 729K 713K 30.46M
Projected Income Statement - Annual - Brooks Laboratories Limited
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manufacturing segment comprises its own manufacturing operations and loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries. The trading segment comprises principal-to-principal trading activities in pharmaceutical products, ingredients, and intermediaries. Its General Products offerings include Liquid Injection (Ampoules), Liquid Injection (Vials), Dry Powder Injections (Vials), Lyophilised Injections, Eye/Ear Drops, and Nasal Drops. The Company's Critical Care Division (CCD), operates through a robust distribution network, delivering injectables to hospitals and healthcare institutions across India.
Employees
347
Date Price Change Volume
23/10/26 ₹57.86 -5.29% 99,200
22/10/26 ₹61.09 +0.51% 54,438
21/10/26 ₹60.78 -6.59% 74,347
19/10/26 ₹65.07 -3.70% 47,904
16/10/26 ₹67.57 -4.05% 122,176
  1. Stock Market
  2. Stocks
  3. BROOKS Stock